Cargando…
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
Current guidelines for hypercholesterolemia treatment emphasize lifestyle modification and lipid‐modifying therapy to reduce the risk for cardiovascular disease. Statins are the primary class of agents used for the treatment of hypercholesterolemia. Although statins are effective for many patients,...
Autores principales: | Ito, Matthew K., Santos, Raul D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215586/ https://www.ncbi.nlm.nih.gov/pubmed/27195910 http://dx.doi.org/10.1002/jcph.766 |
Ejemplares similares
-
Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021) -
Humanised monoclonal antibodies neutralise pertussis toxin by receptor blockade and reduced retrograde trafficking
por: Acquaye‐Seedah, Edith, et al.
Publicado: (2018) -
PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014) -
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
por: Hopkins, Paul N., et al.
Publicado: (2015) -
PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)